Navigation Links
PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
Date:8/28/2007

- Company Plans Sale of Commercial Operations -

- Nuvion(R) Pivotal Trial Program Terminated -

- Company Plans Organizational Realignment -

FREMONT, Calif., Aug. 28 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced a significant strategic change to focus the company on the discovery and development of novel antibodies in oncology and select immunological diseases, following a months-long business and portfolio review.

As a result of this new strategic focus, which does not include cardiovascular disease, PDL plans to sell its commercial assets, including its Cardene(R), Retavase(R) and IV Busulfex(R) products, as well as the ularitide development-stage cardiovascular product. Separately, following a recent and routine Data Monitoring Committee (DMC) evaluation of data from the ongoing RESTORE 1 pivotal trial, the company has decided to terminate the Nuvion (visilizumab) phase 3 program in ulcerative colitis due to insufficient efficacy and an inferior safety profile in the visilizumab arm compared to IV steroids alone. In light of these developments, the company will realign its organization this Fall to support its new strategy.

The company will hold a conference call on Tuesday, August 28th at 5:15 pm ET to discuss these decisions and respond to questions. A webcast of the conference call will be available through the PDL website: http://www.pdl.com.

"We believe our planned strategic shift, which leverages our core technical strengths and expertise in monoclonal antibodies as a development-stage company, is in the best long-term interests of our stockholders," said L.
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... and Hershey, PA (PRWEB) December 19, 2014 ... BJCT), a leading developer and manufacturer of needle-free ... into an agreement with Immunomic Therapeutics, Inc. (“ITI”) ... needle-free injection device with its LAMP™ vaccine platform. ... option for an exclusive Worldwide license to the ...
(Date:12/19/2014)... December 19, 2014 BioPlus Specialty ... pharmacies, announces the promotion of Nick Maroulis, Pharm.D. to ... Pharmacy Services. , In this position, Dr. Maroulis ... also managing the directors of our multi-site pharmacies as ... since 1997 and during that time he has served ...
(Date:12/19/2014)... Calif. , Dec. 19, 2014  Roche (SIX: ... of Bina Technologies, Inc. (Bina), a privately held ... , USA. Bina provides a big data ... generation sequencing (NGS) data. Bina,s proprietary on-market Genomic ... and academic researchers to perform fast and scalable ...
(Date:12/19/2014)... , Dec. 19, 2014 Decision Resources Group ... grow at a 12 percent compound annual growth rate ... the aging population and the increasing adoption of dental ... will also spur demand for dental biomaterials ... implant and periodontal treatments. Other key findings ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3
... Pa., Dec. 1 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,Corporation (Nasdaq: ... announced,that the company will attend the 20th Annual Piper ... The 20th Annual Piper Jaffray Health Care Conference ... December 3, 2008, at the New York,Palace Hotel in ...
... Tigermed Consulting Co., Ltd,a leading Contract Research ... has,established a subsidiary, Hunan Tigermed Xiangya Drug ... (CSU). The establishment of Tigermed Xiangya ... nationwide first-rate Phase,I Clinical Laboratory, and further ...
... COPENHAGEN, December 1 A strong pipeline makes the,Copenhagen Region ... candidates in preclinical and clinical development, Denmark,ranks third in Europe. ... Also in term of ... largest pipeline growth among the countries in Europe. , ...
Cached Biology Technology:Tigermed Sets Up Subsidiary, Hunan Tigermed Xiangya Drug R&D Ltd (Tigermed Xiangya) 2Ernst & Young Benchmarks Danish Biotech Pipeline Third in Europe 2
(Date:12/19/2014)... Dec. 18, 2014  23andMe, Inc., the leading personal ... that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four ... has served as a meeting place for peoples ... and the ongoing mixing of peoples with African, European, ...
(Date:12/17/2014)... Dec. 15, 2014 The Defense Logistics ... easier to detect and prevent counterfeit microcircuits from ... the agency started performing an in-house microcircuit anti-counterfeit ... the authenticity of purchased microcircuits while increasing their ... control measures will be conducted at DLA,s Electronics ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... Even bird brains can get to know an entire continent ... do so, suggests a Princeton research team. The ... way to their winter nesting grounds even after being thrown ... to compensate for the displacement. However, similarly displaced juvenile birds, ...
... today its involvement in an expanded access program ... for phenylketonuria (PKU), a rare genetic metabolic disorder ... can result in severe mental retardation. Currently, there ... program at Nationwide Childrens. Under an expanded ...
... at the Wildlife Conservation Society and other institutions declare ... in South Asia could double the number of tigers ... The study appears in the most recent edition ... examined 157 reserves throughout the Indian subcontinentcomprising India, Bangladesh, ...
Cached Biology News:For migrating sparrows, kids have a compass, but adults have the map 2Nationwide Children's Hospital involved in expanded access program for treatment of PKU 2WCS study finds potential to double tiger numbers in South Asia 2
... to Peroxiredoxin 1 Peroxiredoxin (Prx) ... mammalian members have been known to ... apoptosis. Many isoforms (about 50 proteins), ... acid sequence homology, particularly amino-terminal region ...
... Heat activated ,• Eliminates nonspecific products ... Excellent specificity allows extension through DNA ... ,• Leaves an 'A' overhang ... of GeneChoice DNA Polymerase that remains ...
... beta Synuclein Synucleins are small, soluble ... in certain tumors. The family includes three ... gamma synuclein. The alpha and beta synuclein ... where they are seen mainly in presynaptic ...
NAK/TBK1 (CT) Affinity Purified Polyclonal Antibody...
Biology Products: